Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

BMS-690514

Generic Name: BMS-690514

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₄N_₆O_₂

CAS Number: 859853-30-8

Unique Ingredient Identifier: VKU5X213Q7

Overview

BMS-690514 has been investigated for the treatment of Breast Cancer.

Background

BMS-690514 has been investigated for the treatment of Breast Cancer.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response

Phase 2

Completed

Posted: 2010/07/22

Sponsor:Bristol-Myers Squibb

ID:NCT01167244

Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer

Phase 2

Completed

Posted: 2010/02/15

Sponsor:Bristol-Myers Squibb

ID:NCT01068704

A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

Phase 2

Completed

Posted: 2008/08/29

Sponsor:Bristol-Myers Squibb

ID:NCT00743938

Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors

Phase 1

Completed

Posted: 2007/08/15

Sponsor:Bristol-Myers Squibb

ID:NCT00516451

Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX

Phase 1

Completed

Posted: 2007/05/28

Sponsor:Bristol-Myers Squibb

ID:NCT00479583

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy